ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02442115
Recruitment Status : Recruiting
First Posted : May 13, 2015
Last Update Posted : January 10, 2018
Sponsor:
Information provided by (Responsible Party):
Pat Levitt, PhD, Children's Hospital Los Angeles

Brief Summary:
The clinical manifestation of autism spectrum disorder (ASD) is complex, with medical and mental health disruptions that occur with the three core behavioral criteria used for diagnosis (social behavior, communication, restricted interests/repetitive behavior). Co-occurring medical conditions, such as gastrointestinal dysfunction (GID), often are overlooked when designing research strategies to understand the mechanisms underlying the expression of ASD. This study was initially a collaboration between Children's Hospital Los Angeles (CHLA) and the Children's Hospital at Vanderbilt University. The current research project proposes to recruit subject at CHLA and the Center for Autism and Developmental Disorders (CAND), a Children's Hospital of Orange County and University of California Irvine (UCI) Health collaborative program. In Aim 1, the investigators will characterize GID in pediatric populations with ASD. Over a 12 month period, subjects will receive standard of care for their GID, typically functional constipation. The study population will be characterized with a standardized instrument for diagnosing functional GI disorders in children, the Questionnaire on Pediatric Gastrointestinal Symptoms, and with the clinical acumen of an experienced pediatric gastroenterologist. Nutritional information also will be collected to determine whether there are patterns of GIDs that correlate with dietary and nutritional status. The in-depth characterization and treatment of GIDs in children with ASD will provide a unique way of determining if ASD symptom and GID symptom improvement are related to each other. In Aim 2, the investigators will do in-depth assessment of each subjects functional status for social communication, emotional regulation, cognitive function, speech-language, sensory integration, and a biomarker of oxidative stress. The latter will be measured in urine samples over the course of one year. There are no direct interventions for autism symptoms in this study. Rather, subjects will receive standard of care for the GID diagnosis and secondary effects on ASD symptoms will be evaluated. Our power calculation shows that the investigators will be adequately powered with the proposed study design and recruitment targets. As part of the study, the investigators have developed a collaboration with investigators in the University of Southern California (USC) School of Engineering, in which the investigators will work with them to develop computational tools to assist in the characterization of videotaped Autism Diagnostic Observation Schedule (ADOS-2) assessments.

Condition or disease Intervention/treatment
Autistic Disorder Constipation Gastrointestinal Diseases Other: Treatment of Functional Constipation by

Detailed Description:

Children ages 7 years 0 months to 12 years 11 months will be recruited into 1 clinical group (ASD+/FC+), utilizing the following clinics in Southern California:

CHLA-affiliated Clinics

  • Boone-Fetter Clinic, home of the CHLA Autism Treatment Network
  • University Center of Excellence on Developmental Disabilities (UCEDD) Clinic at CHLA - UC Irvine/Orange County-affiliated clinics
  • Center for Autism and Neurodevelopmental Disorders in Orange County
  • Children's Hospital of Orange County Exclusion criteria include a diagnosed syndromic disorder, prematurity, failure to meet standard birth weight, not enrolled in any ASD treatment program. For each child, the Questionnaire on Pediatric Gastrointestinal Symptoms (QPGS)-Rome III is administered and the child is seen by a board-certified pediatric gastroenterologist. The child will be seen at baseline, 3, 6 and 12 months for their research visits. Treatment of FC in children with ASD is based on the Autism Treatment Network (ATN) modified protocol of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) and includes the following: 1) a thorough dietary history is reviewed and adjusted for introducing a diet rich in fiber (or supplements if able to be tolerated by the child; typically this will be in older children in the study); 2) assessment of abdominal pain, perianal skin tags, hemorrhoids, fissures, rectal exam if needed, frequency of stooling, quality of stool, rectal bleeding, other possible associated symptoms such as reflux/dyspepsia, vomiting, headaches, increase or decrease in appetite; 3) behavioral techniques, such as toileting after meal times, and other strategies are added; and 4) medicine and dietary adjustments are made. At each visit, the following instruments/questionnaires will be administered by a clinical psychologist: 1) social responsiveness scale; 2) Kaufman Brief Intelligence Test; 3) Child Behavior Checklist; 4) Aberrant Behavior Checklist; 5) Pediatric Quality of Life Inventory (Peds QL); 6) Repetitive Behavioral Scale-Revised; 7) Autism Impact Measure; 8) Pearson Short Sensory Profile. The Vineland will be administered at baseline and 12 months. The ADOS-2 will be used at baseline to ensure an ASD diagnosis.

At each visit, subject urine is collected and stored until an assay for the oxidative stress marker F2-isoprostane is measured.

A buccal swab is collected and DNA extracted for future genetic studies.


Study Type : Observational
Estimated Enrollment : 600 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: The MET Signaling System, Autism and Gastrointestinal Dysfunction
Actual Study Start Date : September 2009
Estimated Primary Completion Date : November 2018
Estimated Study Completion Date : November 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Constipation

Group/Cohort Intervention/treatment
ASD with GID
Children with Autism Spectrum Disorder with Functional Constipation will be treated with standard of care defined by NASPGHAN by a pediatric gastroenterologist, and evaluated at 4 visits over 1 year for their medical condition. These children will be enrolled in some ASD treatment program by their parents. The treatment program is not part of the current study. Measures of ASD symptoms will be done at each visit to determine social communication, emotional and cognitive improvement due to the FC treatment. Measures of F2-isoprostane, a marker of oxidative stress, will be done at each visit to determine if FC treatment and ASD symptom improvement relates to improvement in a child's physiology.
Other: Treatment of Functional Constipation by
The NASPGHAN protocol is used by pediatric gastroenterologist to treat functional constipation. Status is monitored at 4 visits and adjustments to treatment are made based on clinical standards and judgment.
Other Name: NASPGHAN standard of care

ASD without GID
Children Autism Spectrum Disorder without Functional Constipation will be evaluated for their ASD symptoms at 4 times over 1 year. These children will be enrolled in some ASD treatment program by their parents. The treatment program is not part of the current study. Measures of F2-isoprostane, a marker of oxidative stress, will be done at each visit to determine if ASD symptom improvement relates to improvement in a child's physiology.



Primary Outcome Measures :
  1. Reduction in F2-IsoProstanes (IsoPs) oxidative stress biomarker [ Time Frame: 1 year ]
  2. Reduction in T-score from Social Responsiveness Scale (SRS-2) (Teacher questionnaire) [ Time Frame: 1 year ]

Biospecimen Retention:   Samples With DNA
Urine sample collection. Saliva sample collection for DNA extraction.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   5 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Children with Autism Spectrum Disorders with and without functional constipation
Criteria

Inclusion Criteria:

  • English or Spanish-speaking of any ethnicity
  • Boys or girls aged 5 years 0 months to 17 years 11 months

    • A clinical diagnosis of functional constipation (FC) for the ASD+/FC+ group, with or without encopresis
    • Clinical assessment of ASD using Diagnostic and Statistical Manual of Mental Disorders (DSM IV or V criteria)
    • ADOS-validated diagnosis of ASD
  • Gestational age between 36 and 42 weeks
  • Birth weight of at least 2500 grams

    • Children with suspected or an existing clinical diagnosis of ASD and FC will be recruited and consented for the study. Assessments and clinical diagnosis may be completed and confirmed through the Baseline study visit for subjects to be eligible.

      • Teacher participation is not required for child participation. However, teacher participation will be requested around the time of child enrollment.

Exclusion Criteria:

  • severe sensory or motor impairments (deafness, blindness;
  • identified inherited metabolic, syndromic, or progressive neurological disorders (including epilepsy, Down Syndrome, Rett Syndrome, Tuberous Sclerosis, Neurofibromatosis, Fragile X Syndrome);
  • a non-functional GID, such as ulcerative colitis, Celiac disease or Hirschsprung's disease;
  • failure to meet birth weight/gestational age as noted above
  • participation in another ASD research study at the same time
  • not enrolled in an ASD intervention program

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02442115


Contacts
Contact: Pat Levitt, PhD TummyTroubles@chla.usc.edu
Contact: Sandra Figueroa, BS 323-361-5284 sfigueroa@chla.usc.edu

Locations
United States, California
Children's Hospital Los Angeles Recruiting
Los Angeles, California, United States, 90027
Contact: Pat Levitt, PhD       Tummytroubles@chla.usc.edu   
Contact: Sandra Figueroa    323-361-5284    sfigueroa@chla.usc.edu   
The Center for Autism & Neurodevelopmental Disorders Recruiting
Santa Ana, California, United States, 92705
Contact: John Donnelly, MD         
Contact: Jennifer Phan    949- 267-0454    phanjt@uci.edu   
Sponsors and Collaborators
Children's Hospital Los Angeles
Investigators
Principal Investigator: Pat Levitt, PhD Children's Hospital Los Angeles

Responsible Party: Pat Levitt, PhD, Simms/Mann Chair in Developmental Neurogenetics, Institute for the Developing Mind, Children's Hospital Los Angeles
ClinicalTrials.gov Identifier: NCT02442115     History of Changes
Other Study ID Numbers: 09-00212
First Posted: May 13, 2015    Key Record Dates
Last Update Posted: January 10, 2018
Last Verified: January 2018

Keywords provided by Pat Levitt, PhD, Children's Hospital Los Angeles:
Autism
Autism Spectrum Disorder (ASD)
Tummy Troubles
Constipation
GI Disorders
Gastrointestinal Disorders
Gastrointestinal
Oxidative Stress
Stomach problems
Behaviors
Autistic
ASD
MET gene
GID
Pediatric
Pediatric GI disorders
Children with Autism
functional constipation

Additional relevant MeSH terms:
Constipation
Autistic Disorder
Gastrointestinal Diseases
Digestive System Diseases
Signs and Symptoms, Digestive
Signs and Symptoms
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Mental Disorders